Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
This study compared Ulcer healing rate of Ilaprazole 20mg or Rabeprazole 20mg in the patients undergone Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer and investigated Prevention of gastrointestinal bleeding.
Gastric Cancer
DRUG: Ilaprazole|DRUG: Rabeprazole
The Ulcer healing rate after endoscopic submucosal dissection, participants will be followed at 8 weeks
The rate of Ulcer size reduction as assessed by measurements of ulcer size change., The rate of Ulcer size reduction(Î”) : \[(Initial ulcer size) - (Ulcer size at 8 weeks)\] / (Initial ulcer size), at 8 weeks after treatment|The quality of ulcer healing as evaluated by the observation of investigator at tracking endoscopy., Apply 0.15% Indigo carmine to scarring of the ulcer and Describe the pattern of the scar as flat, nodular or intermediate at tracking endoscopy., at 8 weeks after treatment|The evaluation of symptom score as assessed by the Korean Gastrointestinal Symptom Rating Scale questionnaire., The Korean Gastrointestinal Symptom Rating Scale questionnaire measured the patient's symptom degree., at 8 weeks after treatment
This study is a Multicenter, Randomized, Parallel and Prospective study to compare Ulcer healing rate of Ilaprazole 20mg or Rabeprazole 20mg in the patients undergone Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer and to investigate Prevention of gastrointestinal bleeding.

Participants are defined as persons who underwent a Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer. For 8 weeks, Participants treated as Ilaprazole 20mg or Rabeprazole 20mg once a day. After treatment, The ulcer healing rate was evaluated by Endoscopy at 4, 8 weeks.